Cogstate, a leading neuroscience technology company, has appointed Dr. Kaycee Sink as Chief Medical Officer. Dr. Sink, formerly Principal Medical Director in Neurodegeneration at Genentech, brings extensive experience in Alzheimer's disease drug development. In her new role, she will:
- Lead Cogstate's support of clinical trials in Alzheimer's and other neurodegenerative disorders
- Advance innovations to improve data quality and trial efficiency
- Advise biopharmaceutical leaders on trial design, endpoint selection, and data quality
- Support efforts to commercialize cognitive assessment technologies for timely diagnoses
Dr. Sink's appointment aims to strengthen Cogstate's value in accelerating Alzheimer's therapeutics development and expanding treatment options. She brings over 20 years of experience in clinical care and research in aging and neurodegenerative disorders.
Cogstate, a leading neuroscience technology company, has established a Scientific Advisory Board (SAB) to enhance its strategy and research initiatives in cognitive assessment and drug development. Chaired by Eric Siemers, MD, the SAB includes notable members from prestigious institutions such as Columbia University and Harvard Medical School. This board aims to provide expert guidance, particularly in areas like Alzheimer’s disease, advancing Cogstate's mission to improve brain health assessments.